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Abstract
The surge in the prevalence of Multidrug-Resistant (MDR) Gram-negative 
bacterial infections with limited treatment led to colistin reusing to treat MDR 
infections. This study aimed to determine economical, simple, and reliable colistin 
susceptibility testing methods as an alternative to the microdilution technique. 
We compared seven colistin susceptibility testing methods, including quantitative 
and qualitative, namely: Disk diffusion, E-test, ComASPTM SensiTest Colistin, 
Colistin broth disk elution, and colistin agar test CHROMagarTM COL-APSE, and 
BD Phoenix ID/AST automated identification and susceptibility testing system 
to the gold standard Broth Microdilution (BMD). Whole-genome sequencing 
was performed on all isolates to determine if the genetic resistant factors affect 
the phenotypic profile of the colistin resistance. Our results revealed that disk 
diffusion is still an ineffective method for measuring colistin susceptibility in 
Gram-negative Bacilli with the highest major error (31.75%), the lowest Kappa 0 
(0%), and categorical agreement (68.25%) values. Phoenix, and CompASPTM 
SensiTest colistin methods have remained superior in reproducibility, sturdiness, 
and simplicity of use, similar to the currently recommended broth microdilution 
procedure; with high sensitivity of 95.56%, and 97.73%, specificity of 95.24, and 
100%, and Kappa values of 0.89 and 0.95, respectively. This study revealed 
that Phoenix, and ComASPTM SensiTest colistin methods are recommended 
for routine microbiology laboratories with a large workload.
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Introduction
Colistin is a cationic polypeptide antibiotic that belongs to 
the family polymyxin, including polymyxin B and polymyxin E 
(colistin). It is the last resort for treating multidrug resistance Gram-
negative Bacilli (MDR-GNB), mainly against Escherichia coli (E. 
coli), Klebsiella pneumoniae (K. pneumoniae), and Pseudomonas 
aeruginosa (P. aeruginosa) [1,2]. It is synthesized naturally by 
Paenibacillus polymyxa and is rapidly bactericidal to Gram-negative 
bacteria. Colistin targets lipid A of Lipopolysaccharide (LPS) in the 
Gram-Negative Bacilli (GNB) outer layer cell membrane. Its central 
role is to inhibit cell membrane function by increasing its permeability 
to absorb polymyxins substances. This increase in permeability 
leads to the destruction of inner macromolecules and cell ions, 
essential for cell survival [2,3]. However, several MDR-GNB bacteria 
developed their defense mechanisms against colistin. This resistance 
development could be either chromosomal or plasmid-mediated. The 
chromosomal resistance can occur due to mutation/insertion in LPS 
biosynthesis genes (lpx, pmrA/B, mgrB, and phoP/Q). On the other 
hand, the plasmid-mediated resistance is acquired by the horizontal 
gene transmission, Encoding Phosphoethanolamine Transferase 
(pEtN) enzymes [4]. As a result, the cell membrane permeability will 
be reduced, and polymyxin binding will be suppressed [1,5-7].
Natural resistance to colistin has been reported on several 
bacteria, mainly chromosomal mutations in some Gram-negative 
species. However, recently plasmid-mediated colistin resistance 
emerged in clinically significant Gram-negative bacilli. The emergent 
resistance was first reported in China in November 2015 through 
the mcr-1 gene [8, 9]. Since then, strains carrying the mcr-1 gene, 
especially E. coli, have been isolated worldwide from humans [10], 
food-producing animals [11], and the environment [12]. Another 
plasmid-carried colistin-resistant gene (mcr-2) was detected in E. coli 
isolates from pigs in Belgium [13]. To date, ten mobile mcr genes have 
been described [14,15]. Colistin was first introduced as an antibiotic 
in 1952 and was used until the early 1980s to treat infections caused by 
GNB. Its use was discontinued because of problems with toxicity, such 
as nephrotoxicity and neurotoxicity [16]. The increase of multidrug 
resistance among clinically significant GNB renewed interest in 
colistin as a last resort therapeutic option for treating MDR-GNB 
bacteria. In clinical practice, there are some situations where clinician 
needs to use colistin; therefore, it is critical for clinical laboratories to 
determine colistin resistance to prevent prolonged administration to 
the patient for whom it would not be effective.
The poor diffusion and binding of colistin to plastics lead to its 
complicated phenotypic resistance testing [17]. In addition, some 
studies noted discrepancies in phenotypic colistin resistance results 
obtained by different methods. Besides, no reference method has 
been demarcated to compare colistin susceptibility testing results 
[4]. As such, both the Clinical and Laboratory Standards Institute 
(CLSI) and the European Committee on Antimicrobial Susceptibility 
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Testing (EUCAST) recommend only Broth Microdilution (BMD) 
[17]. However, the method is impractical for clinical laboratories 
due to the large sample load in routine microbiology laboratories 
[18]. Thus, an alternative, more practical method is needed. Several 
commercial methods are available for colistin Minimum Inhibitory 
Concentration (MIC) measurement, but only a few studies describe 
their efficacy compared to each other. In this context, we conducted 
this study to evaluate and compare the different available quantitative 
and qualitative colistin susceptibility testing methods on some 
GNB to find the feasible colistin test. These methods include disk 
diffusion (Kirby- Bauer test), gradient diffusion method (E- test), 
CHROMagarTM COL-APSE, ComASPTM colistin broth micro-
dilution, colistin broth disk elution, agar dilution, BD Phoenix ID/
AST automated identification, and susceptibility testing system.
Additionally, we performed Whole-Genome Sequencing (WGS) 
to identify the genetic determinants of colistin resistance and find 
if it affects the phenotypic testing method. The study outcomes will 
provide a framework for clinical laboratories to select the appropriate 
method to test colistin resistance.
Materials and Methods
Bacterial strains
Two sets of previously collected bacterial isolates (n=63) were 
employed in this study. The first set comprises isolated human 
pathogens collected from Hamad Medical Corporation (HMC), 
Doha, Qatar, during routine diagnostic testing (n=37). The second 
set was obtained from poultry fecal samples (n=26). Non-duplicate 
bacterial strains were characterized and identified as GNB via Biomic 
V 3 (Giles Scientific, USA) or Matrix-Assisted Laser Desorption 
Ionization-Time of Flight Mass Spectrometry (MAL-DI-TOF MS) 
(Bruker Daltonik GmbH, Leipzig, Germany). These isolates include 
43 strains of E. coli, 18 strains of K. Pneumoniae, and two strains of P. 
aeruginosa. Clinical Isolates were selected because of their resistance to 
third-generation cephalosporins and/or colistin. E. coli isolates from 
poultry fecal samples were obtained from farms using colistin as a 
prophylaxis and growth promotor. The reference strains E. coli ATCC® 
25922, K. pneumoniae ATCC® 700603, and P. aeruginosa ATCC® 
27853 were used as quality control organisms in all experiments. 
This study was approved by Qatar University Institutional Biosafety 
Committee (QU-IBC) number QU-IBC-2020/030.
Phenotypic methods to detect colistin resistance
The subsequent techniques were applied to all 63 isolates 
to determine their susceptibility to colistin, and readings were 
interpreted according to the CLSI [19], NCCLS [20], and Gales et al. 
[21] (Supplementary Table S1).
Disk diffusion method (Kirby-Bauer test)
Bacterial isolates were cultured on nutrient agar plates for 18-
24hrs at 37ºC. After incubation, 2 to 3 pure colonies were suspended 
in a phosphate buffer solution (Atom Scientific, UK) to achieve 
an inoculum equivalent to 0.5 McFarland Standard as measured 
by DensiCHEK PLUS (bioMérieux, France). The suspension was 
then swabbed onto a Mueller-Hinton (MH) agar plate (Himedia, 
Mumbai, India) and allowed to dry completely. Next, antibiotic disks 
impregnated with 10µg colistin (Liofilchem®, Roseto Degli Abruzzi, 
Italy) were applied to the agar surface and incubated at 37ºC for 
24hrs. The zone of inhibition was measured in mm (Figure 1). These 
values were interpreted according to the CLSI [19].
Gradient diffusion method (E-Test)
The isolates were processed similarly to the disk diffusion. The 
E-test strip (Liofilchem, Zona Ind. le, Italy), containing a gradient 
of antibiotic concentrations, was placed onto the prepared MH 
agar plate. The next day, the MIC (the point where the edge of the 
ellipse intersects the strip) in µg/mL was recorded (Figure 1), and 
susceptibility was interpreted according to CLSI [19]. 
CHROMagarTM COL-APSE (selective colistin bacterial 
culture medium) 
The CHROMagarTM COL-APSE (CHROMagar, Paris, 
France) medium was briefly prepared in-house according to the 
manufacturer’s recommendation. The medium was challenged with 
63 different GNB recovered from human and animal samples. The 
media’s ability to detect colistin Gram-negative resistant isolates 
was assessed by direct streaking of a single colony, taken from 
overnight nutrient agar culture onto the prepared CHROMagar 
plate. Then the plate was incubated at 37ºC for 18-24 hrs. The growth 
of typical single colonies appearance, E. coli (pink), Pseudomonas 
(natural pigmentation cream to green), coliforms (metallic blue) was 
considered as colistin-resistant (Figure 2). If the growth was inhibited, 
the isolate was considered sensitive. 
Figure 1: Colistin susceptibility testing by the disk diffusion and E-test 
methods (Liofilchem®). (a) The isolate’s disk diffusion test showed an 
inhibition zone of 8 mm around the colistin disk (right) and MIC of 12µg/mL 
(left). (b) disk diffusion test of the isolate showing inhibition zone of 12 mm 
around the colistin disk (right), inhibition zone with MIC of 1.5 µg/mL (left).
Figure 2: Resistant E. coli and K. pneumoniae growing on CHROMagar 
COL-APSE after overnight incubation at 37ºC. Colistin-resistant E. coli are 
dark pink to reddish (Left), colistin-resistant K. pneumonia is metallic blue 
(right).
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ComASPTM SensiTest Colistin 
ComASPTM Colistin (Liofilchem, Italy) was used as a 
simple version of the BMD and following the manufacturer’s 
recommendations. Succinctly, suspensions equivalent to the 0.5 
McFarland of the isolates were prepared. Further dilutions were 
obtained by diluting 50µL of the bacterial suspensions in 950µL of 
saline. Then 100µL of the diluted suspension was dispensed in the 
panel’s wells. The panel was covered with a lid and incubated in 
ambient air at 37ºC for 16-20 hrs. The first clear well was considered 
the MIC of the examined sample. Concentrations in the ComASPTM 
colistin plate range from 0.25µg/mL to 16µg/mL as depicted in Figure 
3.
Colistin broth disk elution 
This method was performed as described by CLSI [19]. Three 
to five colonies were picked, and turbidity was adjusted to the 
equivalent of a 0.5 McFarland standard, then further diluted to 1:10 
in PBS. Four tubes of MH Broth (Liofilchem®, Roseto degli Abruzzi, 
Italy) were labelled 0 (for control), 1, 2 and 4µg/mL for each isolate, 
corresponding to the concentration of colistin disks (Liofilchem®, 
Roseto degli Abruzzi, Italy) that contains. One colistin disk was added 
to the tube labeled (1µg/mL), two colistin disks to tube labeled (2µg/
mL), and four colistin disks to tube labeled (4µg/mL). The prepared 
inoculum (50µL) was added to all tubes to attain a final concentration 
of approximately 7.5x 105 CFU/mL. The tubes were incubated in a 
shaking incubator (Innova®44, incubator shaker series, Eppendorf, 
Germany) at 33-35°C in ambient air for 16-20 hrs. MIC was read as 
the lowest agar concentration that completely inhibits the growth of 
the tested isolate (Figure 4).
Colistin agar test (CAT)
Colistin stock antibiotic solution was made by adding 15.7mg 
of colistin sulfate salt powder (Potency 19000 U/mg) to 1mL of 
distilled water to obtain a final concentration of 10mg/mL, according 
to the following equation: Weight (mg)=Volume (mL) X colistin 
concentration (µg/mL)/potency (µg/mg) [22]. Colistin agar plates 
with different colistin concentrations were prepared as follows: 
the autoclaved MH agar was allowed to cool to 45-50°C in a water 
bath before aseptically adding colistin (15µL, 30µL, and 60µL to 
150mL warm MH agar to achieve concentrations of 1, 2, and 4µg/
mL, respectively. Subsequently, the prepared MH agar was poured 
into plates labeled with appropriate concentrations. After agar 
solidification, each colistin agar plate of specific concentration was 
divided into six parts labeled with a marker to test up to 6 isolates 
per plate. Then 10µL of ten-fold dilution of McFarland inoculum, 
which was prepared as mentioned above, were streaked onto the 
appropriate portion of each colistin agar plate and incubated at 33-
35°C in ambient air for 16-20 hrs. MIC was read as the lowest agar 
concentration that completely inhibits the tested isolate’s growth 
(Figure 5).
Micro-broth dilution (BMD)
This method involves using small volumes of MH broth 
distributed in sterile, round-bottom 96-plastic well plates described 
by [22,23]. Briefly, two-fold colistin serial dilutions (50µL each), 
starting with the lowest concentration of 0.125µg/mL to second-
highest concentration up to 250µg/mL, were added to the wells in 
each row. Thus, one plate contains seven samples, including E. coli 
ATCC 25922 as a quality control organism, while the last 8th row 
contains each tested isolate’s growth control (Figure 6). 50µL of the 
standardized inoculum (prepared as described above) was added to 
each well within 15 minutes of its preparation. The inoculated 96 well 
plates were incubated at 35±2ºC for 16-18 hrs. MIC was recorded as 
the lowest colistin concentration that completely inhibits bacteria 
growth as detected by the unaided eye.
BD Phoenix ID/AST automated identification and 
susceptibility testing system
BD Phoenix™ M50 (New Jersey, US) was used to determine 
Figure 3: Colistin susceptibility testing by ComASP. Concentrations in the 
ComASPTM colistin plate range from 0.25µg/mL to 16µg/mL. The well on the 
right of the red line indicates the value of the MIC for the isolate.
Figure 4: Colistin Broth-Disk Elution (CBDE). (A) Resistance, with a colistin 
MIC of >4µg/mL (B) Sensitive, with colistin MIC of 1µg/mL.
Figure 5: Colistin agar dilution test indicates the MIC for five isolates and a 
susceptible Control (C) in four different concentrations. A) 0µg/mL, B) 1µg/
mL, C) 2µg/mL and D) 4µg/mL. Inhibition of the growth indicating the MIC of 
the isolates. The plates results: C = susceptible control, 1 = resistance, 2 = 
resistance, 3 = sensitive, “4 = sensitive,” 5 = resistance.
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Antibiotic Susceptibility Testing (AST) following the manufacturer’s 
recommendations. Briefly, few overnight bacterial colonies were 
suspended in the provided BD phoenix broth to achieve an inoculum 
equivalent to 0.5 McFarland Standard. Next 25µl of this prepared 
inoculum solution was transferred to a tube containing Phoenix 
AST broth and a drop of the AST indicator solution. After sample 
preparation was completed, 4.5 mL was added to the BD phoenix 
Gram-negative panel. This panel has a wide range of two-fold doubling 
dilution of several antibiotics (including colistin) and one growth 
control well. The result was read within 16-18 hrs. The Phoenix system 
measures the MIC by microdilution and utilizes a redox indicator to 
detect organism growth in the presence of an antimicrobial agent. 
Organism identification is used in the interpretation of the MIC 
values of each antimicrobial agent.
DNA extraction, sequencing, and bioinformatics
According to the manufacturer’s protocol, genetic DNA was 
extracted from all isolates using a QIAamp® UCP Pathogen mini kit 
(Qiagen, Düsseldorf, Germany). Each isolate’s genomic DNA was 
purified and quantified using a Qubit dsDNA high sensitivity assay 
(Thermo Fisher, Waltham, United States). Then DNA was sent to 
BGI Genomics Co., Ltd., China, for whole-genome sequencing. 
The received raw sequence reads were subjected to a quality check 
and analyzed using CLC genomics workbench v20.0.4 (https://
digitalinsights.qiagen.com). Briefly, the reads were quality assessed, 
trimmed, followed by de novo assembly. Colistin resistance genes 
were identified using ResFinder v 4.1 [24] and the comprehensive 
antibiotic resistance database CARD [25].
Data analysis
The MIC and breakpoint results obtained from the examined 
methods were interpreted according to CLSI [19], NCCLS [20], 
Gales, et al. [21] guidelines and then compared to those obtained by 
the BMD reference method. A Very Major Error (VME) is defined 
as the error indicating a false susceptible result in the tested method 
and resistance in the BMD method’s reference method. In contrast, a 
Major Error (ME) denoted a false resistant result in the tested method 
and susceptible in the reference method. Categorical Agreement (CA) 
percentage is the percentage of isolates with the same results in both 
reference and test methods. Sensitivity, which measures the correctly 
identified positive portion, is characterized as true positive. On the 
other hand, specificity measures the correctly identified negative 
portion, characterized as true negative [26]. Cohen’s Kappa (CK) 
statistics measure inter-rater agreement for categorical items to check 
the test reliability. According to CK interpretation [27], the agreement 
level is none if Kappa value ranges between 0-0.20, minimal; if Kappa 
value (0.21-0.39), weak; if Kappa value (0.40-0.59), moderate; if 
Kappa value (0.60-0.79), strong; if Kappa value (0.80-0.9), and almost 
perfect if the Kappa value is above 0.90. The Positive Predictive Value 
(PPV) is the proportion of bacterial strains giving positive resistant 
test results, which are true resistant. On the other hand, the Negative 
Predictive Value (NPV) is the proportion of bacterial strains giving 
negative resistant test results, which are true sensitive as measured by 
BMD [26]. The sensitivity, specificity, PPV, NPV, CA, ME, VME, and 
CK of each test were calculated using the Equations in Supplementary 
Table S2, based on the BMD reference method.
Results
Overall, 43 (68%) of the studied Gram-negative isolates were 
resistant to colistin by gold standard Broth Microdilution (BMD) 
with resistance detected in 13 (72%) of K. pneumoniae, 2 (100%) P. 
aeruginosa, and 28 (65%) E. coli isolates (Table 1). Quality control 
findings were in line with published standards [19].
Comparison of Colistin disk diffusion to the reference 
BMD method
In all studied isolates, 95.24% (n=60) of the isolates were identified 
as resistant with disk diffusion compared to 68.25% (n=43) using the 
reference method BMD (Table 2, Supplementary Figure 1S(A)). The 
Very Major Error (VME) was not detected 0% (n=0), while 20 isolates 
showed 31.75% Major Error (ME) (Figure 7). Based on the isolates 
tested, the disk diffusion had a sensitivity of 100% and specificity of 
0% for detecting colistin resistance with a Positive Predictive Value 
(PPV) of 68.25% (n=43) and a Negative Predictive Value (NPV) 0% 
(n=0). There was a 63.49% categorical agreement between the disk 
diffusion test and the BMD method. At the same time, the Kappa 
Figure 6: A plate showing MIC of Gram-negative bacilli to colistin by broth 
microdilution method. The isolates from A to D are different strains of E. coli, 
from E to G are different strains of K. pneumonia, and H is a growth control of 
all tested isolates. S is sensitive (MIC ≤2µg/ml). R is resistance (>2 µg/ml). C 
is 0 µg/mL (experimental control for all samples).
Organism Number of isolates
Colistin MIC (µg/mL)
0.25 0.5 1 2 4 8 16 32 64 128
E. coli 43   5 10 3 15 9 1   
K. pneumonia 18   1 4 1 1 1 3 4 3
P. aeruginosa 2     1 1     
Total 63 0 0 6 14 5 17 10 4 4 3
Table 1: Colistin MIC distributions by broth microdilution for the 63 Gram-negative Bacilli isolates.
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value was 0 (0%) (minimal agreement). 
Comparison of E-test to the reference BMD method
There was a 92.06% categorical agreement between the E-test 
and the gold standard method BMD. E-test showed 60.3% (n=38) 
colistin-resistant with MICs of >4 µg/mL, whereas 39.68% (n=25) 
were colistin susceptible with MIC of ≤2 µg/mL. These results were 
compared to the reference method BMD (Table 2, Supplementary 
Figure 1S(B)). The test had 7.94% (n=5) VME and no ME 0% (Figure 
7). The E-test had a sensitivity of 89.58% and a specificity of 100% in 
detecting colistin resistance, a positive predictive value of 100%, and 
a negative predictive value of 80%. The level of agreement by Kappa 
statistics was 0.83 (83%) (strong agreement).
Comparison of ComASPTM sensitest colistin to reference 
BMD method
66.67% (n=42) from isolates were colistin-resistant, and 33.33% 
(n=21) were colistin susceptible using ComASPTM Sensitest 
colistin resistance detection method (Table 2, Supplementary Figure 
1S(c)). The VME was 1.59% (n=1) while ME was 0% (Figure 7). 
The ComASPTM Sensitest Colistin had a sensitivity of 97.73% and 
specificity of 100% in detecting bacterial resistance to colistin with 
Test Number/ percentage of resistance isolates (R) Number/ percentage of susceptible isolates (S)
BMD 43 (68.25 %) 20 (31.75%)
Disk 60 (95.24%) 3 (4.76%)
E-test 38 (60.32%) 25 (39.68%)
ComASPTM Sensitest Colistin 42 (66.67%) 21 (33.33%)
Colistin Broth Disk Elution 40 (63.49%) 23 (36.51%)
Colistin Agar 37 (58.73%) 26 (41.27%)
Phoenix 42 (66.67%) 21 (33.33%)
Table 2: BMD, Disk, E-test, ComASPTM Sensitest Colistin, Colistin Broth Disk Elution, Colistin Agar, and Phoenix susceptibility results.
Figure 7: Comparative evaluation of seven colistin diagnostic tests by categorical agreement, Kappa, sensitivity, and specificity values compared to the gold-
standard method (BMD).
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PPV of 100% and NPV of 95.24%. There was a CA 98.4% (n=62) 
between BMD and ComASPTM Sensitest colistin. (n=62). The Kappa 
value was 0.95 (95%), which shows an almost perfect agreement 
between the two methods.
Comparison of colistin broth disk elution to the reference 
BMD method
A total of 40 (63.49%) of the studied isolates were colistin-
resistant, and 23 (36.51%) were colistin susceptible, as shown in 
Table 2 and Supplementary Figure 1S(D). There was CA between 
Colistin Broth Disk Elution and BMD of 88.89% (n=56) (Figure 
7). Five (7.94%) isolates were VME and 2 (3.17%) ME. The Colistin 
Broth Disk Elution test had a sensitivity of 89.58% and specificity of 
90.91%. PPV of isolates was 95.56%, and NPV was 80%. This method 
had a Kappa value of 0.76 (76%), which shows a moderate level of 
agreement.
Comparison of Agar Dilution to reference BMD method
Overall, 58.7% (n=37) were colistin-resistant with MICs of >2.0 
µg/mL. In comparison, 41.27% (n=26) were susceptible, as presented 
in (Table 2) and (Supplementary Figure 1S(E)). 9.52% (n= 6) of 
the isolates showed VME, and no ME was detected (Figure 7). The 
categorical agreement was 90.48%, and kappa statistics was 0.79 
(79%). This test had a sensitivity of 87.76% and a specificity of 100%, 
with a 100% Positive Predictive Value (PPV) and 76.92% Negative 
Predictive Value (NPV). 
Comparison of chromogenic agar to the reference BMD 
method
Chromogenic agar enhanced the growth of 41(65.08%) of 
isolates; E. coli = 26, K. pneumoniae = 13 and P. aeruginosa = 2. 
While it suppressed the growth of 22 (34.92%), E. coli = 17, and K. 
pneumoniae (Table 3, Supplementary Figure 1S(F)). The method had 
a sensitivity of 91.49% and a specificity of 90.91% (Figure 7). The CA 
between chromo-genic agar and BMD method was 90.48%. There 
were 4 (6.35%) VME and 2 (3.17%) ME. PPV was 95.56%, and NPV 
was 83.33%. Kappa value for chromogenic agar method showed a 
moderate level of agreement (0.77, 77%).
Comparison of Phoenix to reference BMD method
A total of 42 (66.67%) isolates were colistin-resistant, while 21 
(33.33%) were colistin susceptible by Phoenix (Table 2, Supplementary 
Figure 1S(G)). There was a CA of 95.24% (n=60) between Phoenix 
and BMD (Figure 7). The VME was 3.17% (n=2), and the ME was 
1.59% (n=1). Phoenix method had 95.56% sensitivity and 95.24% 
specificity, with PPV of 97.73% and NPV of 90.91%. The Kappa value 
was 0.89 (89%), indicating a strong level of agreement.
Genetic determinant of colistin resistance
As depicted in Table 4, a total of 43 isolates of E. coli were 
divided into four types based on genetic determinants of colistin 
resistance. Of these, 26 were plasmid resistance (harbor mcr1-1); 2 
were chromosomal modifications; one isolate harbor mcr1-1 plus 
chromosomal modification, and 14 were sensitive, not presenting any 
colistin-resistant genetic determinant. Whereas K. pneumoniae has 
11 isolates that contain chromosomal colistin resistance, 2 isolates 
harbored mcr1-1 plus chromosomal modifications, and 5 were 
sensitive. The resistance of the two isolates of P. aeruginosa was due 
to the chromosomal modifications. 
Discussion
The use of colistin to treat infections caused by multidrug-
resistant Gram-negative Bacilli, including E. coli, K. pneumoniae, 
and P. aeruginosa, is being increasingly described in many countries 
[28]. Additionally, antimicrobial susceptibility by phenotypic 
methods, including the colistin method, is currently the cornerstone 
of Antimicrobial Resistance (AMR) surveillance [17]. Nevertheless, 
susceptibility testing for colistin remains challenging mainly due to 
its intrinsic properties. Importantly, there is no agreement between 
colistin susceptibility testing methodologies [29,30]. The technique 
most frequently used in routine laboratories is disc diffusion, but it 
has been shown to be inefficient [17,29,31]. This study tested colistin 
resistance using seven methods and compared them to BMD as a 
gold standard, which is the most reliable method [17,19]. However, 
this method consumes time, effort, and money in routine medical 
laboratories [18]. Furthermore, the inclusion of representative strains, 
both susceptible and resistant, is critical in avoiding bias against a 
positive or negative outcome. Therefore, the strain panel used in this 
study was selected to ensure that both resistant and sensitive strains 
are included.
The most widely used method in routine laboratories, disk 
diffusion, is inefficient; due to weak colistin diffusion in Mueller 
Hinton agar [32]. Based on our findings, the disk diffusion method 
using a 10 µg/mL colistin disk was not a reliable method for colistin 
susceptibility testing with specificity 0% and Kappa value of 0 (0%) 
(Figure 7). These findings agree with several studies [31,33,34] 
reporting an inaccurate disk method for determining colistin 
susceptibility. In addition, an unacceptably high rate of very major 
errors ranging from 5% to 11% was recorded [31,33,34]. In our study, 
we did not report any very major errors (0%); however, we observed 
a high percentage of major errors (31.75%) with a low categorical 
Bacteria Resistance (Growth)No. /percentage
Susceptible (No growth)
No. /percentage
E. coli 26 (41.27%) 17 (26.98%)
K. pneumonia 13 (20.63%) 5 (7.94%)
P. aeruginosa 2 (3.17%) 0 (0%)
Table 3: Chromogenic agar susceptibility results.
Organism Number of isolates
Colistin resistance type
mcr1-1 GMR mcr1-1 & GMR Not present
E. coli 43 26 2 1 14
K. pneumonia 18 0 11 2 5
P. aeruginosa 2 0 2 0 0
Total 63 26 15 3 19
Table 4: Genetic determinant of colistin resistance among 63 Gram-negative Bacilli isolates.
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agreement of 68.25% to the reference BMD method that supports the 
inaccuracy described by the previous studies.
 Lo-Ten-Foe et al. [33]; Tan and Ng. [35]; Behera et al. [36] 
reported that E-test is a fast and reliable alternative method for 
determining colistin susceptibility. Our comparison portrayed a 
strong correlation (Kappa, 83% and Categorical agreement 92%) 
between broth microdilution and E-test. No false resistant (ME) 
results by E-test were detected, whereas a 7.94% false susceptible 
(VME) was exhibited (Figure 7). The E-test has been shown to have 
high concordance (>96%) in correlation with broth microdilution 
in previous studies [33,36]. In convergence with our findings, these 
studies reported one to four percentages of false susceptibility (VME) 
but no false resistant results (ME).
ComASPTM Sensitest Colistin is a modified BMD method but 
more straightforward with a shorter turnaround time, as different 
colistin concentrations are already prepared and exist in the test 
panels. The outcomes of this method were the most perfect compared 
to all other tested methods. Our data demonstrated a categorical 
agreement of 98.4% compared to BMD. Only one isolate was colistin-
resistant by BMD and susceptible by ComASPTM Sensitest, resulting 
in a VME value of 1.59%, and no ME was documented (Figure 7). The 
method has a high specificity of 100%, whereas sensitivity was 97.73%. 
A PPV and NPV of 100% and 95.24%% were recorded, respectively. 
The significantly high Kappa value (95%) of ComASPTM Sensitest 
proposed that this method can be an alternative to BMD. Thus, 
ComASPTM Sensitest can be accomplished faster with less effort and 
required accuracy in large laboratories with a high workload. Our 
findings were concordant with Osei Sekyere, et al. [37]; Carretto et 
al. [1]. 
Colistin broth disk elution endorsed by [19] has low cost and 
needs less effort. According to Simner et al. [38], colistin broth disk 
elution is a reproducible and accurate method and can alter BMD. 
Nevertheless, our test results revealed that the Categorical agreement 
between colistin broth disk elution and BMD is 88.89%. Five isolates 
with VME and 2 with ME. The method had a moderate agreement 
(Kappa value of (76%) compared to BMD. The dissimilarity in 
results could be ascribed to the use of disks produced by different 
manufacturers.
Colistin agar test was recently introduced to be superior to 
broth dilution methods in reproducibility and robustness [39] for 
determining colistin MICs. CLSI [19] lately recommended CAT, an 
adaptation of the agar dilution process, as a test for colistin resistance 
in Enterobacterales and P. aeruginosa. No ME was observed with the 
agar dilution method; however, 9.52% VME was detected mainly 
among E. coli isolates. Gonzales Escalante et al. [39] suggested adding 
an extra plate of colistin supplemented with EDTA, a well-known 
mcr1-1 inhibitor, to the CAT method; this was recently implemented 
for the precise detection of mcr1-1 producers. Numerous studies have 
demonstrated excellent agreement between colistin agar dilution 
and BMD [40,41]. Our study depicted a solid categorical agreement 
(90.48%) between the agar dilution method and the gold standard 
BMD (Figure 7).
In this study, we also used CHROMagarTM COL-APSE 
chromogenic agar to detect colistin resistance. Our numbers show 
specificity and sensitivity of 91.49% and 90.91%, respectively, whereas 
a recent study by Sekyere et al. [37] recorded a sensitivity and 
specificity of 82.05% and 66.67%. On the other hand, Abdul Momin 
et al. [4] reported specificity and sensitivity of 100% in their study. 
Sekyere et al. [37] evaluated the media’s performance using different 
amounts of cultured bacteria; this might be a constraint in our study 
that needs further investigation. It is remarkable to note that this 
media suppresses the growth of susceptible strains, but some grew on 
it, as demonstrated by our study and the previous studies. The CA was 
90.48%, where six isolates had different results by the chromogenic 
agar and BMD. Four isolates showed VME, and two displayed ME. 
The Kappa value has a moderate level of agreement with 0.77 (77%). 
Therefore, it reduces the chance of choosing chromogenic agar as an 
alternative to BMD.
BD Phoenix™ M50. This method showed a CA of 95.24%, VME of 
3.17%, and ME of 1.59%. Thus, the sensitivity and the specificity had 
almost the same values of 95.56% and 95.24%. In addition, the method 
had a Kappa value of 0.89 (89%), indicating a solid agreement level. In 
contrast, previous studies showed that Phoenix is a deprived method 
and has unacceptable and inaccurate results with low specificity and 
sensitivity [42,43]. Furthermore, a study done by Jayol, et al. [44] 
mentioned that the Phoenix system could detect plasmid-mediated 
colistin-resistance bacteria. Conversely, our study results indicated 
that Phoenix could detect both plasmid and gene-mediated colistin 
resistance, regardless of the resistance level.
To date, ten mobile mcr genes have been described [9,14,15]. In 
our study, we did Whole-Genome Sequencing (WGS) for 63 isolates. 
A high resistance rate to colistin antibiotic was mainly detected 
among E. coli isolates that harbor mcr1-1 type of genetic determinant 
of colistin resistance. While most of K. pneumoniae isolates had 
chromosomal colistin resistance mutation, as demonstrated by Table 
4. Genotypic methods, in particular, are unlikely to detect all of the 
chromosomal mutations responsible for the majority of phenotypic 
colistin resistance in clinical screening settings [45]. Therefore, 
a negative PCR molecular test result cannot be used to predict 
colistin susceptibility because the test cannot rule out the existence 
of chromosomal mechanisms of resistance or even the presence of 
a novel mcr gene. To avoid this limitation, mcr genes and identified 
chromosomal mutations that cause colistin resistance will be possible 
with WGS. Although strains with novel resistance mechanisms will 
reduce the sensitivity and negative predictive value, WGS is the most 
detailed approach for detecting all currently known putative colistin 
resistance mechanisms. As new resistance mechanisms are described, 
it will also allow retrospective analysis of sequencing results. The 
agreement between phenotypic and genotypic test results will increase 
our understanding of colistin resistance mechanisms.
Conclusion
In conclusion, as we continue to spectate an increasing emergence 
of colistin resistance in Gram-negative multidrug-resistant bacteria, 
reliable and rapid colistin susceptibility testing is anticipated. This 
study found that disk diffusion is still an ineffective method for 
measuring colistin susceptibility in Gram-negative Bacilli. On the 
other hand, Phoenix and CompASPT SensiTest colistin methods 
have remained superior in reproducibility, sturdiness, and simplicity 
of use with a performance similar to the current recommended BMD 
procedure. These findings may rationalize and recommend validating 
J Bacteriol Mycol 8(5): id1181 (2021)  - Page - 08
Eltai NO Austin Publishing Group
Submit your Manuscript | www.austinpublishinggroup.com
these approaches using more samples and including other Gram-
negative bacilli to develop a globally accepted consistent method for 
colistin susceptibility testing. If standardized, these methods can be 
executed in laboratories with a high workload and colistin resistance 
surveillance programs. However, our study did not ensure any 
relation between the type of colistin resistance genetic determinant 
(chromosomal/plasmid-mediated) and the performance of the 
specific colistin susceptibility test.
Acknowledgment
This study was supported by (UREP26-024-1-002) grant from 
the Qatar National Research Fund (QNRF), a member of the Qatar 
Foundation. The authors would like to thank Hana Abdelrahman and 
Lubna Abu rub for the technical assistance.
Funding
This research was supported by a grant (UREP26-024-1-002) 
from the Qatar National Research Fund (QNRF), a member of the 
Qatar Foundation.
Author Contributions
Conceptualization, N.E. methodology, N.S., H.A., N.M., M.R., 
K.A., K.A.; software, N.E, N.S and H.A.; validation, N.S. and H.A..; 
formal analysis, N.E.; investigation, N.E and S.Z .; resources, N.E.; 
data curation, N.E and S.Z.; writing-original draft preparation, N.S 
and H. A.; writing-review and editing, N.E. and S. Z; visualization, 
N.E and S. Z.; supervision, N.E.; project administration, N.E.; funding 
acquisition, N.E. All authors have read and agreed to the published 
version of the manuscript”.
References
1. Carretto E, Brovarone F, Russello G, Nardini P, El-Bouseary MM, Aboklaish 
AF, et al. Clinical Validation of SensiTest Colistin, a Broth Microdilution-Based 
Method to Evaluate Colistin MICs. Journal of Clinical Microbiology. 2018; 56.
2. Gwozdzinski K, Azarderakhsh S, Imirzalioglu C, Falgenhauer L, Chakraborty 
T. An Improved Medium for Colistin Susceptibility Testing. Journal of Clinical 
Microbiology. 2018; 56.
3. Patricia M. Tille In: Bailey &amp; Scott’s diagnostic microbiology. 14th ed. St. 
Louis, Missouri: Elsevier; 2017: 160-169.
4. Abdul Momin MH, Bean DC, Hendriksen RS, Haenni M, Phee LM, Wareham 
DW. CHROMagar col-apse: A selective bacterial culture medium for the 
isolation and differentiation of colistin-resistant gram-negative pathogens. 
Journal of Medical Microbiology. 2017; 66: 1554-1561.
5. McPhee JB, Bains M, Winsor G, Lewenza S, Kwasnicka A, Brazas MD, et al. 
Contribution of the PhoP-PhoQ and PmrA-PmrB Two-Component Regulatory 
Systems to Mg2+-Induced Gene Regulation in Pseudomonas aeruginosa. 
Journal of Bacteriology. 2006; 188: 3995-4006.  
6. Fernández L, Jenssen H, Bains M, Wiegand I, Gooderham WJ, Hancock RE. 
The Two-Component System CprRS Senses Cationic Peptides and Triggers 
Adaptive Resistance in Pseudomonas aeruginosa Independently of ParRS. 
Antimicrobial Agents and Chemotherapy. 2012; 56: 6212-6222.
7. Ly NS, Yang J, Bulitta JB, Tsuji BT. Impact of Two-Component Regulatory 
Systems PhoP-PhoQ and PmrA-PmrB on Colistin Pharmacodynamics in 
Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 2012; 
56: 3453-3456.
8. Hu Y, Liu F, Lin IY, Gao GF, Zhu B. Dissemination of the mcr-1 colistin 
resistance gene. The Lancet Infectious Diseases. 2016; 16: 146-147.
9. Liu Y-Y, Wang Y, Walsh TR, Yi L-X, Zhang R, Spencer J, et al. Emergence 
of plasmid-mediated colistin resistance mechanism MCR-1 in animals and 
human beings in China: a microbiological and molecular biological study. The 
Lancet Infectious Diseases. 2016; 16: 161-168.
10. Gröndahl-Yli-Hannuksela K, Lönnqvist E, Kallonen T, Lindholm L, Jalava 
J, Rantakokko-Jalava K, et al. The first human report of mobile colistin 
resistance gene, mcr-1, in Finland. APMIS. 2018; 126: 413-417.
11. Shen Z, Wang Y, Shen Y, Shen J, Wu C. Early emergence of mcr-1 in 
Escherichia coli from food-producing animals. The Lancet Infectious 
Diseases. 2016; 16: 293.
12. Zurfuh K, Poirel L, Nordmann P, Nüesch-Inderbinen M, Hächler H, Stephan 
R. Occurrence of the Plasmid-Borne mcr-1 Colistin Resistance Gene in 
Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in River 
Water and Imported Vegetable Samples in Switzerland. Antimicrobial Agents 
and Chemotherapy. 2016; 60: 2594-2595.
13. Xavier BB, Lammens C, Ruhal R, Kumar-Singh S, Butaye P, Goossens H, et 
al. identification of a novel plasmid-mediated colistin-resistance gene, mcr-2, 
in Escherichia coli, Belgium. Eurosurveillance. 2016; 21.
14. Carroll LM, Gaballa A, Guldimann C, Sullivan G, Henderson LO, Wiedmann 
M. Identification of Novel Mobilized Colistin Resistance Gene mcr-9 in a 
Multidrug-Resistant, Colistin-Susceptible Salmonella enterica Serotype 
Typhimurium Isolate. MBio. 2019; 10. 
15. Gelbíčová T, Baráková A, Florianová M, Jamborová I, Zelendová M, 
Pospíšilová L, et al. Dissemination and Comparison of Genetic Determinants 
of mcr-Mediated Colistin Resistance in Enterobacteriaceae via Retailed Raw 
Meat Products. Frontiers in Microbiology. 2019; 10.
16. Catchpole CR, Andrews JM, Brenwald N, Wise R. A reassessment of the 
in-vitro activity of colistin sulphomethate sodium. Journal of Antimicrobial 
Chemotherapy. 1997; 39: 255-260.
17. WHO. The detection and reporting of colistin resistance. 2018.
18. Sharma A, Agrawal M. Colistin Susceptibility for Carbapenem-Resistant 
Gram-Negative Bacilli; Comparative Study of E-test and Vitek 2 Compact™ 
with Broth Microdilution. Galore International Journal of Health Sciences and 
Research. 2019; 4: 110-115.
19. CLSI. Performance standards for antimicrobial susceptibility testing. 30th. 
Wayne, PA: Clinical and Laboratory Standards Institute. 2020.
20. Hutchens TT. NCCLS: objectives, organization, and activities. Pathologist. 
1981; 35: 605-608.
21. Gales AC, Reis AO, Jones RN. Contemporary Assessment of Antimicrobial 
Susceptibility Testing Methods for Polymyxin B and Colistin: Review of 
Available Interpretative Criteria and Quality Control Guidelines. Journal of 
Clinical Microbiology. 2001; 39: 183-190.  
22. CLSI. Performance standards for antimicrobial susceptibility testing. 26th. 
M100-S23. USA. 2013.
23. CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that 
grow aerobically. 9th. M07-A9. Wayne, PA: Clinical and Laboratory Standards 
Institute, USA. 2012.
24. Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, et al. 
ResFinder 4.0 for predictions of phenotypes from genotypes. Journal of 
Antimicrobial Chemotherapy. 2020; 75: 3491-500.
25. Alcock BP, Raphenya AR, Lau TT, Tsang KK, Bouchard M, Edalatmand A, 
et al. CARD 2020: antibiotic resistome surveillance with the comprehensive 
antibiotic resistance database. Nucleic Acids Research. 2020; 48: D517-D25.
26. Trevethan R. Sensitivity, Specificity, and Predictive Values: Foundations, 
Pliabilities, and Pitfalls in Research and Practice. Frontiers in Public Health. 
2017; 5.
27. McHugh ML. Interrater reliability: the kappa statistic. Biochemia Medica. 
2012; 22: 276-282.
28. Biswas S, Brunel J-M, Dubus J-C, Reynaud-Gaubert M, Rolain J-M. Colistin: 
an update on the antibiotic of the 21st century. Expert Review of Anti-infective 
Therapy. 2012; 10: 917-934.
29. CLSI. Performance standards for antimicrobial susceptibility testing. 27th. 
M100S. Wayne, PA: Clinical and Laboratory Standards Institute. 2017.
J Bacteriol Mycol 8(5): id1181 (2021)  - Page - 09
Eltai NO Austin Publishing Group
Submit your Manuscript | www.austinpublishinggroup.com
30. EUCAST. The European Committee on Antimicrobial Susceptibility Testing. 
Breakpoint tables for interpretation of MICs and zone diameters. 2017.
31. Tan TY. Comparison of three standardized disc susceptibility testing methods 
for colistin. Journal of Antimicrobial Chemotherapy. 2006; 58: 864-867.
32. Luis Esaú Ló-J, Christian Rodolfo R-G, Melissa He-D, Claudia Adriana 
C-C, Rodolfo G-C, Rafael F-C. An alternative disk diffusion test in broth and 
macrodilution method for colistin susceptibility in Enterobacteriales. Journal 
of Microbiological Methods. 2019.
33. Lo-Ten-Foe JR, de Smet AM, Diederen BM, Kluytmans JA, van Keulen 
PH. Comparative Evaluation of the VITEK 2, Disk Diffusion, Etest, Broth 
Microdilution, and Agar Dilution Susceptibility Testing Methods for Colistin 
in Clinical Isolates, Including Heteroresistant Enterobacter cloacae and 
Acinetobacter baumannii Strains. Antimicrobial Agents and Chemotherapy. 
2007; 51: 3726-3730.
34. Galani I, Kontopidou F, Souli M, Rekatsina P-D, Koratzanis E, Deliolanis 
J, et al. Colistin susceptibility testing by Etest and disk diffusion methods. 
International Journal of Antimicrobial Agents. 2008; 31: 434-439.
35. Tan TY, Ng SY. Comparison of Etest, Vitek and agar dilution for susceptibility 
testing of colistin. Clinical Microbiology and Infection. 2007; 13: 541-544.
36. Behera B, Mathur P, Das A, Kapil A, Gupta B, Bhoi S, et al. Evaluation 
of susceptibility testing methods for polymyxin. International Journal of 
Infectious Diseases. 2010; 14.
37. Osei Sekyere J, Sephofane AK, Mbelle NM. Comparative Evaluation of 
CHROMagar COL-APSE, MicroScan Walkaway, ComASP Colistin, and 
Colistin MAC Test in Detecting Colistin-resistant Gram-Negative Bacteria. 
Scientific Reports. 2020; 10.
38. Simner PJ, Bergman Y, Trejo M, Roberts AA, Marayan R, Tekle T, et al. Two-
Site Evaluation of the Colistin Broth Disk Elution Test to Determine Colistin In 
Vitro Activity against Gram-Negative Bacilli. Journal of Clinical Microbiology. 
2019; 57.
39. Gonzales Escalante E, Yauri Condor K, Di Conza JA, Gutkind GO. Phenotypic 
Detection of Plasmid-Mediated Colistin Resistance in Enterobacteriaceae. 
Journal of Clinical Microbiology. 2019; 58.
40. Moskowitz SM, Garber E, Chen Y, Clock SA, Tabibi S, Miller AK, et al. 
Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates 
of Pseudomonas aeruginosa and Stenotrophomonas maltophilia. Journal of 
Antimicrobial Chemotherapy. 2010; 65: 1416-1423.
41. Turlej-Rogacka A, Xavier BB, Janssens L. et al. Evaluation of colistin stability 
in agar and comparison of four methods for MIC testing of colistin. European 
Journal of Clinical Microbiology & Infectious Diseases: Official Publication of 
The European Society of Clinical Microbiology. 2018; 37.
42. Pfennigwerth N, Kaminski A, Korte-Berwanger M, Pfeifer Y, Simon M, Werner 
G, et al. Evaluation of six commercial products for colistin susceptibility 
testing in Enterobacterales. Clinical Microbiology and Infection. 2019; 25: 
1385-1389.
43. Vourli S, Dafopoulou K, Vrioni G, Tsakris A, Pournaras S. Evaluation of 
two automated systems for colistin susceptibility testing of carbapenem-
resistant Acinetobacter baumannii clinical isolates. Journal of Antimicrobial 
Chemotherapy. 2017; 72: 2528-2530.
44. Jayol A, Nordmann P, Lehours P, Poirel L, Dubois V. Comparison of methods 
for detection of plasmid-mediated and chromosomally encoded colistin 
resistance in Enterobacteriaceae. Clinical Microbiology and Infection. 2018; 
24: 175-179.
45. Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: 
acquired and intrinsic resistance in bacteria. Frontiers in Microbiology. 2014; 
5.
